One of the factors required for successful retroviral transduction is contact between viral particles and target cells. We hypothesized that combining agents that improve virus-target cell interaction via different mechanisms will increase transduction efficiency. We examined the transduction efficiency of leukemic K562 cells, primary normal and chronic myelogenous leukemia CD34
Introduction
Transduction of human progenitors and stem cells with retroviral vectors could lead to successful treatment of patients with cancer and a number of congenital disorders. 1 Unfortunately, retroviral transduction of human hematopoietic stem cells is poor. This is due to multiple different factors, including low level expression of retroviral receptors, G 0 /G 1 cell cycle status of progenitors, and possible induction of differentiation of primitive hematopoietic progenitors when one attempts to induce cell proliferation. 2, 3 Other factors include low viral titer, short half-life of the retroviral vector and Brownian movement of the retrovirus. 4, 5 Chuck et al 6 have shown that in a static transduction system, the majority of viral particles do not interact with the target cells before degradation. To overcome these limitations, higher titer virus has been used. However, increased viral titer does not always correlate with enhanced gene transfer efficiency due to elevated levels of inhibitors or metabolic toxins secreted by the packaging cells and an equal increase in the production of empty vectors which compete with intact vectors for binding to the retroviral receptors. 7, 8 Although serum-free viral supernatant may reduce the level of inhibitors Correspondence: CM Verfaillie, Department of Medicine, Box 806, 420 Delaware St SE, Minneapolis MN 55455, USA Received 27 August 1999; accepted 19 October 1999 and inactivators, the viral titer in serum-free supernatant is lower than in serum containing medium. 9, 10 It had been shown that several modifications to the transduction procedure that may enhance the interaction between viral particles and target cells can improve retroviral transduction. These include the transwell flow-through system, recombinant fibronectin fragment (CH296), cationic lipids, calcium precipitation, centrifugation and use of polyamines. 6, [11] [12] [13] We hypothesized that by combining approaches to enhance virus-cell interaction based on different mechanisms, retroviral transduction of hematopoietic progenitors would be additively or synergistically improved. We show that a combination of cationic lipids and CH296 significantly improves transduction not only of hematopoietic cell lines, but also of normal and leukemic primary CD34 + cells.
Materials and methods

Subjects and cell preparation
Bone marrow was obtained from normal donors and blood or marrow from nine patients with Ph + , BCR/ABL + chronic phase CML, after informed consent using guidelines approved by the Committee on the Use of Human Subjects in Research at the University of Minnesota. Bone marrow or blood mononuclear cells were selected by Ficoll-Hypaque (specific gravity 1.077) (Sigma Diagnostics, St Louis, MO, USA) density gradient centrifugation.
Purification of primitive progenitors
Bone marrow or blood mononuclear cells from CML patients or normal volunteers were enriched for CD34
+ cells by passing over a MACS column twice as recommended by the manufacturer (Miltenyi Biotec, Auburn, CA, USA). Resultant cells were stained with CD34-PE (Becton Dickinson, Palo Alto, CA, USA) and analyzed by FACS-Calibur (Becton Dickinson) using isotype-control IgG-PE. The purity of CD34 + cells ranged between 85 and 98%.
Preparation of retroviral supernatant
G1Na-PA317 producing cells were grown to near confluence in Dubecco's modified Eagle medium (DMEM) (Gibco BRL, Gaithersburg, MD, USA) supplemented with 10% fetal calf serum (FCS) (HyClone, Logan, UT, USA). Media were replaced with either Iscove's modified Dubecco's medium (IMDM) (Gibco BRL) supplement with 20% FCS or serum-free media. The latter consisted of phosphate-free RPMI 1640 (Gibco BRL) (supplemented with 20% BIT 9500 (Stem Cell Technology, Vancouver, Canada) plus 40 g/ml of low density lipoprotein (Sigma), 10 g/ml of desulfated, N-acetylated Leukemia heparin (Seikagaku, Tokyo, Japan), 10 −4 m ␤-mercaptoethanol with growth factors as described below. Viral supernatant was harvested after incubation for 24 h at 32°C with 5% CO 2 . All supernatants were shown to be free of replication-competent helper virus. The viral titer of supernatant made in IMDM plus 20% FCS and serum-free media ranged from 1.2-2.6 × 10 
Transwell flow-through system
Cells suspended in IMDM + 20% FCS were plated in collagencoated transwells (0.4 m pore size, 6.5 mm diameter), (Costar, Cambridge, MA, USA) or non-collagen-coated transwells (Falcon, Franklin Lakes, NJ, USA). Media were drained and removed from the lower compartment before transduction. Five sequential times, we added 200 l viral supernatant to the transwell, let it drain through and removed the filtrate from the lower compartment before adding the next 200 l.
Preparation of cationic lipids
Ten l of different cationic lipids including pfx1 to pfx8 (PerFect Lipid Kit; Invitrogen, San Diego, CA, USA), lipofectamine and DMRIE (Gibco BRL), and cytofectin (a kind gift from Glen Research, Sterling, VA, USA) were mixed with 1 ml retroviral supernatant at room temperature for 30 min with gentle shaking. The mixture was then used to transduce K562 cells or CD34 + cells.
Coating of recombinant fibronectin fragment (CH296)
Twenty-four-well tissue-culture-treated plates (Costar) or transwells either with or without collagen coating were incubated with 50 or 200 l of 50 g/ml CH296 (RetroNectin; Takara, Otsu, Japan) for 2 h according to the manufacturer's instructions.
Transduction of K562 leukemic cells
K562 cells (American Type Culture Collection, Rockville, MD, USA) were maintained in DMEM supplemented with 20% fetal calf serum at 37°C with 5% CO 2 . K562 cells were subcultured 24 h before transduction. Transductions were done using serum containing retroviral supernatant with or without CH296, cationic lipids or transwell flow-through system alone or in combination. The transduced cells were harvested 18 h later and replated in methylcellulose (Fisher, Chicago, IL, USA; final concentration of 1.12%) IMDM supplemented with 30% FCS with or without 1 mg/ml (active antibiotic) G418 (Gibco BRL) for 12 days. Transduction efficiency was determined by the number of colonies in G418-containing media divided by the number in the absence of G418.
Transduction of primary bone marrow CD34 + cells
One thousand to 10 000 normal or CML CD34 + cells were pre-stimulated for 48 h with low-phosphate serum-free medium supplemented with 20 ng/ml Flt3-L (Immunex, Seattle, WA, USA), 20 ng/ml stem cell factor (Amgen, Thousand Oaks, CA, USA), 2 ng/ml IL3 (R&D System, Minneapolis, MN, USA). On days 3 and 4, cells were transduced with lowphosphate serum-free viral supernatant in the presence of the same cytokines and transduction agents (Figure 1 ). Transduced cells were plated with clonogenic methylcellulose medium containing 30% FCS, 3 IU/ml erythropoietin (Amgen), and supernatant of the bladder carcinoma cell line 5637 (7.5%) with or without 1 mg/ml G418 for 2 weeks. 14 Transduction efficiency was determined in the same way as for K562 cells.
Measurement of viral titer in transwell filtrate
The titer of viral supernatants before and after transwell filtration was determined using NIH-3T3-TK− cells with serial dilution and colony forming assay using G418 0.5 mg/ml. 15 
Statistics
Results of experimental points obtained from multiple experiments were shown as mean ± standard error of the mean (s.e.m.). Statistical significance was determined by using Student's t-test.
Results
The effect of cationic lipids on cell viability and retroviral transduction
The effect of different cationic lipids on retroviral transduction efficiency of K562 cells varied considerably and did not correlate with the cytotoxicity (Figure 2) . Addition of either lipofectamine or pfx-7 significantly improved transduction efficiency (four-fold) with minimal to moderate cytotoxicity. Lipofectamine was therefore chosen to further study the effect of lipid on the transduction efficiency of K562 cells and primary CD34
+ cells alone or in conjunction with other agents.
Augmentation of retroviral transduction by using cationic lipids, CH296 and transwell flow-through system alone or in combination
We next tested the effect of CH296, cationic lipids and the transwell flow-through system alone or in combination on the transduction efficiency of K562 cells (Figure 3) . Lipofectamine or CH296 improved transduction of K562 cells by two-fold (P Ͻ0.05). The combination of lipofectamine and CH296 further improved transduction (P = 0.157 compared with lipofectamine and 0.0357 compared with CH296). Transduction of K562 cells in a transwell flow-through system alone also improved transduction three-fold (P Ͻ 0.005 compared to no transwell). Transduction efficiency was similar when transwells coated with or without collagen were used. As retroviral supernatants drained more easily through collagen-coated transwells these were used in studies on primary CD34 + cells.
The effect of the different agents alone or in combination on transduction of primary CD34 + cells is more pronounced
We then examined the effect of these same three manipulations on the transduction of normal human bone marrow Experimental procedures. K562 leukemic cells or primary normal or CML CD34 + cells were transduced using three different methods alone or in combination. Transduction efficiency was determined by enumeration of colony-forming cells in selective or nonselective media.
Figure 2
Effect of different cationic lipids on transduction efficiency of K562 cells. Cytotoxicity varied with different lipids. Lipofectamine and pfx7 significantly improved retroviral transduction with minimal cytotoxicity. n = 3; Statistics: mean ± s.e.m.
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+ CFC. The addition of lipofectamine or CH296 improved transduction efficiency by 10-and 20-fold (P = 0.169 and Ͻ0.05), respectively. The combination of lipids and CH296 had synergistic effects and improved transduction 30-fold. Of interest, the transwell flow-through system alone also improved transduction of normal CD34
+ CFC up to 30-fold (P Ͻ 0.05). Coating the transwells with CH296, and further addition of lipofectamine did not significantly further increase transduction.
CH296 and lipids improved transduction of CML CFC as is seen for K562 cells
We also tested the effect of CH296 and lipofectamine either alone or in combination on CML CFC transduction ( Figure  4b ). CML CFC have defective integrins and therefore adhere poorly to fibronectin. 16 Consistent with this is our finding that transduction of CML CFC improved only two-fold with CH296, whereas normal CFC transduction improved 20-fold
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Figure 3
Effect of lipofectamine, CH296 and transwell on the transduction of K562 cells. K562 cells were transduced in the presence or absence of lipofectamine, CH296 and transwell flow-through system, alone or in combination. Cells were then plated in clonogenic assay to determine the % G418 resistant cells. All three methods improved transduction efficiency. The combination of lipofectamine and CH296 had additive effects on transduction. n = 3; Statistics: mean ± s.e.m. *: P Ͻ 0.05 compared to no-coating/no-transwell setting; **: P Ͻ 0.05 compared to no coating/transwell setting by Student's t-test.
with CH296. Lipofectamine alone improved transduction three-fold and had synergistic effects with CH296.
Transwell flow-through system concentrates virus in the upper compartment of transwell
We then examined if coculture of CD34 + cells with the virus producer cell line which was separated from the CD34 + cells by a transwell membrane would also improve transduction efficiency. Transduction efficiency was significantly lower in CD34
+ CFC plated in a transwell above the producer cell line than in the transwell flow-through system ( Figure 5 ). This sug-
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Figure 4
Effect of lipofectamine, CH296 and transwell flowthrough system on the transduction efficiency of primary CD34
+ cells from (a) normal bone marrow (n = 7) or (b) CML bone marrow or blood (n = 9). Normal and CML CD34 + cells were selected as described in the Methods. They were transduced in the presence or absence of lipofectamine, CH296 and transwell flow-through system, alone or in combination. Cells were then plated in clonogenic assay to determine the % G418 resistant progenitors. All three methods significantly improved retroviral transduction in normal CD34
+ cells whereas the combination of cationic lipids and CH296 had additive effects on the transduction efficiency. In CML, transduction in the presence of CH296 improved transduction only two-fold. This was significantly enhanced when combined with lipofectamine. Statistics: mean ± s.e.m. Student's t-test. * : P Ͻ 0.05 compared to nocoating/no-transwell setting, ** P Ͻ 0.05 compared to nocoating/transwell setting; #P Ͻ 0.05 cationic lipid + CH296 vs others.
gests that improvement of transduction in the transwell flowthrough might be due to improved virus-target cells interaction by overcoming the limitation of Brownian movement, and retention of viruses on the transwell membrane. To confirm this, we measured the viral titer in supernatants before and after filtration through the transwell. The titer of transwell filtrates was 10-to 100-fold lower than the unfiltered supernatant, suggesting that 90-99% of viral particles were retained in the transwell (data not shown). The viral titer in the upper compartment of transwells placed above the producer cell line was also 100-fold lower than in the viral supernatant in the lower compartment. CD34 + cells were plated in transwells above the G1Na producer feeder. Alternatively, CD34
+ cells were plated in transwells placed in empty wells, and G1Na containing medium was filtered through the transwell. After 3 days, the percent G418 positive CFC was examined. Transduction of CD34
+ CFC was not improved in a transwell above the viral producer feeder. n = 3; Statistics: mean ± s.e.m. Student's t-test. *P Ͻ 0.05.
Discussion
Retrovirus-mediated gene transfer is one of the possible ways to correct genetic defects and treat malignancies. 1, 2 In addition, several studies have shown that transfer of genes that render stem cells drug resistant may allow administration of chemotherapeutic agents after transplantation to further eliminate malignancies. 1, 2, 17 For instance, our group has shown that transfer of a retroviral vector containing anti-BCR/ABL antisense sequence and a methotrexate resistance gene may allow for treatment of patients with Ph + CML or Ph + ALL with MTX after transplant, further decreasing minimal residual disease. 17 However, poor transduction efficiency of human hematopoietic stem cells and progenitor cells is one of the major hurdles for successful gene therapy. [1] [2] [3] 9 In this study, we examined the effects that cationic lipids, the recombinant fibronectin fragment, CH296, and the transwell flow-through system have on the retroviral transduction of human CD34 + cells. It has been hypothesized that these three methods improve retroviral transduction by different mechanisms.
We found a three-to 10-fold enhanced transduction of K562 cells or primary CD34
+ CFC when done in the presence of lipofectamine. Some studies have suggested that cationic lipids may function like polyamines (eg protamines) and reduce electrostatic repulsion between virus and target cells. 11, 18 An alternative hypothesis shown in the study of adenovirus infection is that cationic lipids may cause aggregation of viral particles and improve infection by enhancing contact of target cells and precipitated viruses. 19 It is important to keep in mind that cationic lipids can have toxic effects on cells, as we showed that eight out of 11 lipids tested on K562 cells cause significant cell death.
As has been shown by Williams et al, we found that the recombinant fibronectin fragment, CH296, improved retroviral transduction of human normal CD34
+ cells by 20-fold. 20, 21 + cells in an additive or synergistic fashion. This is especially of great importance for transduction of CD34
+ cells from patients with CML, in whom transduction in the presence of CH296 only marginally improves due to defective adhesion of the cells to fibronectin.
We confirm that the transwell flow-through system alone markedly improves transduction of both K562 and CD34 + CFC. We present evidence that this is likely due to the fact that Ͼ99% of viruses are retained in the transwell. This is somewhat surprising, as the pore size of the transwell membrane is larger than the virus size. As the viral envelope is heavily charged, we hypothesize that retention of virus may be due to charge on the CH296 or collagen-coated on the transwell membrane. Thus, if one could develop a 'clinical scale' transwell flow-through system, clinical transduction of CD34 + cells may be significantly improved. This would be especially useful when high viral titer is not obtainable. We and others have shown that stromal support may be crucial to induce proliferation of hematopoietic stem cells and prevent their differentiation. [22] [23] [24] Use of the transwell flowthrough system in which a transwell can be placed over stromal feeders that secrete the necessary factors for stem cell proliferation should allow HSC maintenance and proliferation while they are being transduced.
